E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Early onset forms of Metachromatic Leucodystrophy. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10029205 |
E.1.2 | Term | Nervous system disorders |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10067609 |
E.1.2 | Term | Metachromatic leukodystrophy |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10027433 |
E.1.2 | Term | Metabolism and nutrition disorders |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary goal of the trial is the assessment of tolerance (safety) of the intracerebral adminsitration of a single dose of AAVrh.10cuARSA |
|
E.2.2 | Secondary objectives of the trial |
Evaluate the efficacy of intracerebral administration of a single dose of a AAVrh.210cuARSA to stop the disease progression |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Boys or girls with an ealry onset form of MLD - Age between 6 months ans 4 years, inclusive - Interval between age of first symptoms and age of inclusion muyst be 12 or less months - Diagnostic of MLD based on the measurement of ARSA activity in leukocytes and the accumulation of sulfatides in urine, along with normal activity of at least one other sulfatase - Informed consent signed up and willingness for monitoring 2 years after treatment - Normal values for standard laboratory tests. |
|
E.4 | Principal exclusion criteria |
- Absence of ARSA protein by immunocytochemistry and/or ELISA - Gestational age < 32 weeks of amenorrhoea and age < 1 year - Brain atrophy with a subdural space > 10mm in the frontal region. -MLD MRI severity score >14 - Performance IQ<70 at WPPSI-III or cognitive function < 3rd percentile at the Bayley's test of infant development - If age>16 months at inclusion, inability to walk few steps alone OR inability to walk few steps with support on one side along with inability to stand up alone - Impossibility for anesthesia - Malignancy cardiac malformation, liver dysfunction, or renal dysfuncion - Neurological disorder, except benign, not related to MLD - Any other clinically significant untreated co-morbid medical condition as determined by the clinical investigator, including cardiac, pulmonary or kidney disease. - MRI impossibilty - Evoked potential impossibility - Participation to another therapeutic clinical trial for MLD - Unaffiliated to any French health insurance or any other European National Health Insurance |
|
E.5 End points |
E.5.1 | Primary end point(s) |
A) SAFETY Early follow-up: safety or neurosurgical procedure (M0-M1) - Standard clinical and neurological exam and monitoring of adverse events associated to the procedure - Standard laboratory tests - CT scan - Brain MRI Follow-up after the neurosurgical procedure (M1-M24) - Standard clinical and laboratory tests and adverse event monitoring - Brain MRI
B) Primary efficacy endpoint MLD neurological severity score |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
A) SAFETY Early follow-up: safety or neurosurgical procedure (M0-M1) - Standard clinical and neurological exam and monitoring of adverse events associated to the procedure: day +1, +3, +7, +10 and months +1 - Standard laboratory tests: day +3, +10, and months +1 - CT scan: within 36 hours of the procedure - Brain MRI day +6 and month +1 Follow-up after the neurosurgical procedure (M1-M24) - Standard clinical and laboratory tests and adverse event monitoring months 1,3,6,9,15 18 and 24 - Brain MRI months +3, +9, +15 and +24
B) Primary efficacy endpoint MLD neurological severity score at months +1, +3, +6, +12 +18 and +24 |
|
E.5.2 | Secondary end point(s) |
Motor scores (GMFM, Ashworth and ICARS) Neurological evaluation Cognitive functions (Bayey Scales of Infant Development MLD severity MRI score, MRI-DTI parameters, measurement of cerebral atrophy and spectroscopy Neuroelectrophysiological tests (peripheral nerve condution velocity, visual, auditory and somatosensory evoked potentials) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Motor scores (GMFM, Ashworth and ICARS): at months +1, +3 for GMFM ans Ahshworth tests only, and +6, +12, +18and +24 for all tests Neurological evaluation at each visit. Cognitive functions (Bayey Scales of Infant Development at months +3, +9, +15 and +24. MLD severity MRI score, MRI-DTI parameters, measurement of cerebral atrophy and spectroscopy at months +1, +3, +6, +9, +15 and +24. Neuroelectrophysiological tests (peripheral nerve condution velocity, visual, auditory at months +3, 15 and +24 and somatosensory evoked potentials) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | Yes |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |